Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility.

Arnell, Christopher; Bergman, Martin; Basu, Dhiman; Kenney, James T; Withers, Johanna B; Logan, Jennifer; Harashima, Jeraldine Lim; Connolly-Strong, Erin

Arnell, Christopher; Bergman, Martin; Basu, Dhiman; Kenney, James T; Withers, Johanna B; Logan, Jennifer; Harashima, Jeraldine Lim; Connolly-Strong, Erin.

Affiliation

Arnell C; Scipher Medicine Corporation, Waltham, MA.
Bergman M; Drexel University College of Medicine, Philadelphia, PA.
Basu D; Medical City North Hills and Texas Health HEB, Colleyville, TX.
Kenney JT; JTKENNEY, LLC, Waltham, MA.
Withers JB; Scipher Medicine Corporation, Waltham, MA.
Logan J; LLC, Salt Lake City, UT.
Harashima JL; Scipher Medicine Corporation, Waltham, MA.
Connolly-Strong E; Scipher Medicine Corporation, Waltham, MA.

J Manag Care Spec Pharm ; 27(12): 1734-1742, 2021 Dec.

Article de En | MEDLINE | ID: mdl-34669487

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyarthrite rhumatoïde / Budgets / Résultat thérapeutique / Analyse coût-bénéfice / Antirhumatismaux Type d'étude: Guideline / Health_economic_evaluation / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: J Manag Care Spec Pharm Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google